KalVista Pharmaceuticals Inc. has announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first oral on-demand treatment for hereditary angioedema $(HAE)$. The findings were presented at the 20th German Allergy Congress in Düsseldorf, Germany, held from October 2-4, 2025. Results from the studies demonstrated that sebetralstat enabled rapid and effective treatment of HAE attacks among European participants, with a median time to treatment of 16 minutes and a median time to beginning of symptom relief of 1.6 hours. The KONFIDENT-S interim analysis included 69 participants from 15 European countries who collectively treated 999 attacks. The data also highlighted barriers associated with injectable therapies, such as injection-site reactions and difficulty accessing medication, based on a patient survey. EKTERLY is now approved in the European Union, with a launch planned in Germany this quarter and additional European launches expected in 2026 and beyond.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006039455) on October 06, 2025, and is solely responsible for the information contained therein.
Comments